News | Stents Peripheral | February 08, 2016

Stentys Launches Self-Expanding Below-The-Knee Drug-Eluting Stent

Device will launch first in Germany and Belgium following successful results of PES BTK-70 trial

Stentys, commercialization, BTK stent, below-the-knee arteries

February 8, 2016 — Stentys announced the first distribution agreements for its drug-eluting stent for treating below-the-knee (BTK) arteries in Germany and Belgium, making it the first self-expanding drug-eluting stent commercialized for this indication in Europe.

The Stentys stent obtained CE Marking for the BTK indication at the end of 2015 following the results achieved by the PES BTK-70 study, where it prevented amputation in 99 percent of the 70 patients treated for critical limb ischemia (CLI). The trial treated patients suffering from CLI of class 4 and 5 in the Rutherford scale with a Stentys paclitaxel-eluting stent from January 2012 to May 2013 in five hospitals. The primary endpoint was the 12-month primary patency rate defined as absence of restenosis (≥50 percent) or occlusion within the originally treated lesion based on angiography verified by Core Lab. At 12 months, the primary patency rate was 73 percent, freedom from target-lesion revascularization was 79 percent and freedom from amputation was 99 percent.

For more information: www.stentys.com

Related Content

Lithotripsy Safe and Effective in Calcified Stenotic Peripheral Arteries
News | Peripheral Artery Disease (PAD) | December 04, 2018
New results from the DISRUPT PAD II study showed no perforations, embolization, reflow or abrupt closures with the...
Lutonix 014 Drug-Coated Balloon Safe and Effective Below the Knee
News | Peripheral Artery Disease (PAD) | November 07, 2018
The Lutonix Drug-Coated Balloon (DCB) showed statistically significant safety equivalence with a standard percutaneous...
Lokai Medical to Distribute NuCryo Vascular PolarCath Balloon Dilatation System in U.S.
News | Peripheral Artery Disease (PAD) | August 14, 2018
NuCryo Vascular announced that the company has signed a commercialization agreement with Lokai Medical, a specialty...
PQ Bypass Effective in Treating Extremely Long SFA Lesions at 12 Months
News | Peripheral Artery Disease (PAD) | July 02, 2018
The PQ Bypass Detour System showed promising 12-month durability for patients with extremely long blockages in the...
SCAI Releases Consensus Guidelines for Femoral-Popliteal Arterial Interventional Device Selection
News | Peripheral Artery Disease (PAD) | May 15, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) has released new guidelines to address the...
SCAI Launches Diagnosis and Treatment Toolkit for Peripheral Artery Disease
News | Peripheral Artery Disease (PAD) | May 14, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) announced the launch of the SCAI PAD Diagnosis and...
Critical Limb Ischemia Treatment Shows No Improvement at Three Months
News | Peripheral Artery Disease (PAD) | March 23, 2018
Patients with foot ulcers or gangrene who received the experimental drug JVS-100 did not show evidence of faster wound...
FDA Clears Corindus CorPath GRX for Peripheral Vascular Interventions
Technology | Peripheral Artery Disease (PAD) | February 20, 2018
Corindus Vascular Robotics Inc. announced today that it received 510(k) clearance from the U.S. Food and Drug...
News | Peripheral Artery Disease (PAD) | December 29, 2017
December 29, 2017 — iVascular announced the release of the new Oceanus 14 Pro percutaneous transluminal angioplasty (
Overlay Init